Clinical Trials
Vimseltinib shows activity in tenosynovial giant cell tumor in phase 2 trial
Stacchiotti et alCancer

Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm driven by colony-stimulating factor 1 (CSF1) gene dysregulation. For patients whose disease is not amenable to surgical resection, systemic intervention targeting the CSF1 receptor (CSF1R) is necessary. Vimseltinib, an oral switch-control kinase inhibitor of CSF1R, was evaluated in the multicenter, open-label, phase 2 expansion portion of an ongoing trial (NCT03069469) in adults with histologically confirmed, non-surgical TGCT.
Participants received vimseltinib at the recommended phase 2 dose of 30 mg twice weekly. Cohort A included patients with no prior specific anti-CSF1/CSF1R therapy (n = 46; prior imatinib or nilotinib allowed), and Cohort B included patients who had received prior specific anti-CSF1/CSF1R agents (n = 20). Primary objectives were to evaluate safety and antitumor activity, while secondary endpoints assessed active range of motion (ROM) and patient-reported health outcomes.
Over mean follow-up periods of 23 months for Cohort A and 19 months for Cohort B, vimseltinib demonstrated durable antitumor activity with best overall response rates of 64% (29 of 45) and 37% (7 of 19), respectively. Treatment was generally well-tolerated, with the majority of treatment-emergent adverse events being grade 1 or 2 and no evidence of drug-induced liver injury or cholestatic hepatotoxicity. Additionally, most patients achieved clinically meaningful improvements in active ROM, pain, stiffness, physical function, and health status.
Key Takeaways
- In adults with non-surgical tenosynovial giant cell tumor, oral vimseltinib achieved best overall response rates of 64% (29/45) in anti-CSF1/CSF1R–naive patients and 37% (7/19) in those with prior specific CSF1/CSF1R inhibitor exposure over mean follow-ups of 23 and 19 months, respectively.
- Vimseltinib exhibited a manageable safety profile characterized mostly by grade 1/2 adverse events, with no recorded instances of drug-induced liver injury or cholestatic hepatotoxicity.
- Treatment with vimseltinib provided meaningful functional and symptomatic gains across cohorts, including improvements in active range of motion, pain, stiffness, physical function, and overall health status.
Read the original sourceCancer
